Search filters

Filters

Clear All

Phase

  • 33
  • 94
  • 1
  • 80
  • 37
  • 1
  • 118
  • 387
  • 180
  • 13
  • 19
  • 355
  • 382
  • 5
  • 4
  • 383

Found 387 Neoplasms trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Precision Promise Platform Trial for Metastatic Pancreatic Cancer

Precision Promise Platform Trial for Metastatic Pancreatic Cancer

All genders
Precision Promise is a multi-center, seamless Phase 2/3 platform trial designed to evaluate multiple regimens in metastatic pancreatic cancer. The goal of the platform is to find effective therapies for pancreatic cancer. The platform will rapidly and efficiently test multiple novel drugs and combinations compared to standard of care therapy …
 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver

18 years - 99 years
All genders
Phase 2
Interventional
This trial studies how well pevonedistat alone or in combination with chemotherapy (paclitaxel and carboplatin) works in treating patients with bile duct cancer of the liver. Pevonedistat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as …
 A Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

A Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

18 years - 99 years
All genders
Phase 1
Interventional
A study to evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB680 (CD73 inhibitor) in combination with AB122 (programmed cell death-1 inhibitor) and standard chemotherapy (nab-paclitaxel [NP] and gemcitabine [Gem]) in participants with advanced pancreatic cancer.

UPCC 21520: The LIMIT KRAS Mutant NSCLC Trial: Lysosome Inhibition to Enhance MAPK Inhibition Targeting KRAS Mutant NSCLC: A Phase 2 Open Label Trial of Binimetinib and Hydroxychloroquine in Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer

All genders
Phase 2
This study will evaluate using hydroxychloroquine (HCQ) along with binimetinib as an effective method for treating cancer. All patients will receive binimetinib at a standard dose approved for other cancers. The dose of HCQ will also be fixed based on ongoing phase I studies. Eligible subjects will have lung cancer …

Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection Of Lung Malignancies.

18 years - 99 years
All genders
Phase 2
Interventional
The purpose of this research study is to learn if the investigational study drug, pegsitacianine, helps in seeing the primary lung cancer tumor and identifying any additional cancerous tissue present in the lung for removal at the time of standard of care cancer surgery. Each participant will receive a single …

EVALUATING THE UPTAKE OF [18F] FLUOROESTRADIOL (FES) BPET/DBT IN PRIMARY BREAST CANCER TO MEASURE THE LOCALIZED EXTENT OF ESTROGEN RECEPTOR POSITIVE DISEASE

18 years - 99 years
Female
Interventional
The purpose of this study is to test a new scanner device that combines two types of imaging called Breast Positron Emission Tomography (BPET) and Digital Breast Tomosynthesis (DPT) for imaging of a radioactive imaging drug called 18F-Fluoroestradiol (FES), as a diagnostic device for imaging estrogen receptor (ER) positive breast …
 TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum

TACE Ax HCQ: Phase IB Study of Hepatic Chemoembolization Plus Axitinib and Hydrochlorquine for Liver-Dominant Metastatic Adenocarcinoma Of The Colon And Rectum

18 years - 99 years
All genders
Phase 1
Interventional
Liver metastases are a leading cause of death among patients with metastatic colorectal cancer. Duration of disease control is short following 2nd-line or later systemic therapy. Liver-directed therapy such as TACE has a higher response rate and improves PFS, but the benefit is still limited. Cancer cells escape ischemic cell …

Phase Ib Trial of ASP8374 and Cemiplimab in Recurrent Malignant Glioma Patients

All genders
Phase 2
Primary Objectives Cohort 1: To determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of ASP8374 when administered with cemiplimab among recurrent malignant glioma participants. Cohort 2: To determine if neoadjuvant immune checkpoint blockade (ICB) with ASP8374, cemiplimab and the combination of ASP8374 plus cemiplimab will induce …
 A071701 Genomically-Guided Treatment Trial in Brain Metastases

A071701 Genomically-Guided Treatment Trial in Brain Metastases

18 years - 99 years
All genders
Interventional
This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK or PI3K. Medications that target these genes such …
 UPCC 35217: A Phase 1B/2  Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy

UPCC 35217: A Phase 1B/2 Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy

All genders
Phase 2
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.
51 - 60 of 387